SCHEMBL17199499

CC1C(O)[C@H](O[C@@H]2OC(CO)[C@H](O)C(O)[C@@H]2O)[C@H](CO)C[C@H]1O[C@@H]1C(O)[C@H](O)C(CO)O[C@@H]1OCC(O[C@H](CO)O[C@@H]1C(CO)O[C@@H](O[C@@H]2C(CO)O[C@@H](C)[C@@H](C)C2O)[C@@H](C)C1O)[C@@H](O)[C@@H](C)O[C@H]1O[C@H](CO)[C@@H](O)C(O)C1O[C@@H]1OC(CO)[C@H](O[C@@H]2OC(CO)[C@H](C)C(O[C@]3(C(=O)O)C[C@@H](O)[C@@H](N)C(C(O)C(O)CO)O3)[C@@H]2O)C(O)[C@@H]1C

nearest known ligand 0.40

Predicted protein targets (top 5)

	gene	UniProt	supporting neighbours	confidence
▸	MAG	P20916	6/20	0.39

▸	SIGLEC7	Q9Y286	6/20	0.39

▸	SELP	P16109	2/20	0.38

▸	SELL	P14151	2/20	0.38

▸	SELE	P16581	4/20	0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compound	similarity	top predicted	shared targets
SCHEMBL17199601	0.94	SIGLEC7 (0.43)	MAGSIGLEC7SELPSELLSELE
SCHEMBL15849853	0.92	MAG (0.46)	MAGSIGLEC7SELPSELLSELE
SCHEMBL17211556	0.91	MAG (0.46)	MAGSIGLEC7SELPSELLSELE
SCHEMBL15176939	0.88	SIGLEC7 (0.44)	MAGSIGLEC7SELPSELLSELE
SCHEMBL16301515	0.88	SIGLEC7 (0.44)	MAGSIGLEC7SELPSELLSELE
SCHEMBL16190390	0.88	SIGLEC7 (0.44)	MAGSIGLEC7SELPSELLSELE
SCHEMBL15849877	0.87	SIGLEC7 (0.45)	MAGSIGLEC7SELPSELLSELE
SCHEMBL18934138	0.85	SIGLEC7 (0.46)	MAGSIGLEC7SELPSELLSELE
SCHEMBL17199639	0.83	SIGLEC7 (0.46)	MAGSIGLEC7SELPSELLSELE
SCHEMBL17211533	0.81	SIGLEC7 (0.44)	MAGSIGLEC7SELPSELL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

Patent	Title	Assignee	Published	Priority	Filing	Country	Status
US-20150299337-A1	GLYCOSYLATED LINKER, COMPOUND CONTAINING GLYCOSYLATED LINKER MOIETY AND PHYSIOLOGICALLY ACTIVE SUBSTANCE MOIETY OR SALT THEREOF, AND METHODS FOR PRODUCING SAID U OR SALT THEREOF	GLYTECH INC (JP)	2015-10-22	—	—	US	disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

Patent	Title	Text reads most about	Predicted target · text-rank
US-20150299337-A1	GLYCOSYLATED LINKER, COMPOUND CONTAINING GLYCOSYLATED LINKER MOIETY AND PHYSIOLOGICALLY ACTIVE SUBSTANCE MOIETY OR SALT THEREOF, AND METHODS FOR PRODUCING SAID U OR SALT THEREOF	CD44, CSGALNACT1, UGGT1	MAG 644/4885SIGLEC7 8/4885SELP 156/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.